Hit-to-Lead Optimization Strategy in Drug Discovery, Upcoming Webinar Hosted by Xtalks

TORONTO, July 22, 2020 /PRNewswire-PRWeb/ -- In vitro biochemical assays make possible the high throughput screening (HTS) of large compound libraries. A successful HTS campaign is typically viewed as one that identifies large numbers of diverse chemical series hits as potential starting points on the way to a clinical candidate. These hits are typically weakly active in a primary screen and do not necessarily possess drug like characteristics. Hit-to-Lead optimization is now a key process in drug discovery that explores the chemistry and biology of hits to focus efforts on the most promising starting points so that development time and costs are saved.

What makes a promising starting point for a drug discovery program? In this webinar, strategies to triage hits and focus efforts will be discussed.

Join Mark Wolf, Head of Medicinal Chemistry at AMRI and Doug Kitchen, Head of CADD at AMRI in a live webinar on Thursday, August 13, 2020 at 11am EDT (4pm BST/UK).

For more information or to register for this event, visit Hit-to-Lead Optimization Strategy in Drug Discovery.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

SOURCE Xtalks

Related Links

https://xtalks.com